- ￥3220 - 21030
- Sino Biological
- 北京
- 10084-H08H
- 2026年01月26日
研选同类产品更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 用户评价
- 文献和实验
- 技术资料
- 保存条件：
-20℃ to -80℃
- 保质期：
12个月
- 英文名：
Recombinant Human PD-L1 / B7-H1 / CD274 Protein (His Tag)
- 库存：
99
- 供应商：
北京义翘神州科技股份有限公司
- 规格：
1.00 mg/100.00 µg/200.00 µg
| 规格： | 1.00 mg | 产品价格： | ￥21030.0 |
|---|---|---|---|
| 规格： | 100.00 µg | 产品价格： | ￥3220.0 |
| 规格： | 200.00 µg | 产品价格： | ￥3870.0 |
重组人 PD-L1 / B7-H1 / CD274 蛋白 (His标签)（产品说明）
蛋白名称：Human PD-L1 / B7-H1 / CD274 Protein (His Tag)
蛋白构建：A DNA sequence encoding the N-terminal segment (Met 1-Thr 239) of the extracellular domain of human B7-H1 (NP_054862.1) was expressed with a C-terminal polyhistidine tag.
表达宿主：HEK293 Cells
蛋白纯度：> 98 % as determined by SDS-PAGE
蛋白活性：1. Measured by its binding ability in a functional ELISA. Immobilized human B7-H1 at 20 μg/ml (100 μl/well) can bind human PD1 with a linear range of 0.032-0.8 μg/ml. 2. Using the Octet RED System, the affinity constant (Kd) of PD-1 Protein, Human, Recombinant (Fc Tag) (Cat. 10377-H02H) bound PD-L1 Protein, Human, Recombinant (His Tag) (Cat. 10084-H08H) was 19.2nM.
蛋白内毒素：< 1.0 EU per μg of the protein as determined by the LAL method
预测N端：Phe 19
蛋白分子量：The recombinant mature human B7-H1 comprises 232 amino acids and predicts a molecular mass of 26.8 kDa. As a result of glycosylation, the human B7-H1 migrates as an approximately 35-38 kDa protein in SDS-PAGE under reducing conditions.
蛋白NP号：NP_054862.1
蛋白氨基酸序列：Met1-Thr239
蛋白标签：C-His
蛋白保存条件：Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
用户评价
暂无用户评价
文献和实验1, Schofield DJ, et al. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.mAbs, PubMed ID: 33397194
2, Wang F, et al. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.Neoplasia (New York, N.Y.), PubMed ID: 33529880
3, Xing Y, et al. New electrochemical method for programmed death-ligand 1 detection based on a paper-based microfluidic aptasensor.Bioelectrochemistry (Amsterdam, Netherlands), PubMed ID: 33677221
4, Li M, et al. Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo.Scientific reports, PubMed ID: 33707569
5, Jeong S, et al. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.Journal for immunotherapy of cancer, PubMed ID: 34230109
6, Banta KL, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.Immunity, PubMed ID: 35263569
7, He B, et al. PDL1Binder: Identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors.Frontiers in microbiology, PubMed ID: 35910615
8, Yi M, et al. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.Journal for immunotherapy of cancer, PubMed ID: 36460337
9, Parkinson J, et al. The RESP AI model accelerates the identification of tight-binding antibodies.Nature communications, PubMed ID: 36709319
10, Wang F, et al. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction.International journal of molecular sciences, PubMed ID: 36835382
11, Zhang Y, et al. Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers.Journal for immunotherapy of cancer, PubMed ID: 38580333
12, Yao Y, et al. Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2.European journal of nuclear medicine and molecular imaging, PubMed ID: 39155310
13, Xu X, et al. A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer.Cancers, PubMed ID: 39272910
14, Mao C, et al. In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy. Nature communications, PubMed ID:39521768
15, Sun M, et al. Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposing. Bioorganic chemistry, PubMed ID:39418845
HIS 标签蛋白纯化效果不理想，宝宝心里苦呀。今天，小编来跟大家一起找找原因。 纯化所得组分中没有收集到重组的 HIS 标签蛋白。该问题主要可以分为以下两个方面： 1、HIS 标签蛋白没有结合到填料上就流穿了 原因一 超声的功率不对。超声功率过高，容易导致蛋白炭化；功率过低，蛋白释放不出来。 建议 改变超声功率，同时可以在超声前加入溶菌酶。 原因二 结合缓冲液条件不合适。 建议 检查结合缓冲液中是否有影响结合的因素，如：金属离子螫合剂、强还原剂、过高的咪唑浓度。同时，优化缓冲
蛋白标签（protein tag）是指利用DNA体外重组技术，与目的蛋白一起融合表达的一种多肽或者蛋白，以便于目的蛋白的表达、检测、示踪和纯化等。随着技术的不断发展，研究人员相继开发出了具有各种不同功能的蛋白标签。 一、 新型蛋白标签 蛋白标签应用极为广泛，但仍有两个问题不容忽视：（1）蛋白标签以DNA形式编码，它需要转录并翻译成蛋白后才能发挥作用，而这种作用方式本身就是一种缺陷。例如，常用的荧光蛋白标签，在显微镜下观察时，其显像不如人工合成的荧光基团好，但是这种人工合成的荧
His 标签蛋白纯化效果不理想，宝宝心里苦呀。今天，小编来跟大家一起找找原因。 纯化所得组分中没有收集到重组的His标签蛋白。该问题主要可以分为以下两个方面： 1、His标签蛋白没有结合到填料上就流穿了 原因一 超声的功率不对。超声功率过高，容易导致蛋白炭化；功率过低，蛋白释放不出来。 建议 改变超声功率，同时可以在超声前加入溶菌酶。 原因二 结合缓冲液条件不合适。 建议 检查结合缓冲液中是否有影响结合的因素，如：金属离子螯合剂、强还原剂、过高的咪唑浓度。同时，优化缓冲液的pH、盐
技术资料暂无技术资料 索取技术资料
